Mega Lifesciences Valuation Multiples

Mega Lifesciences Overview

About Mega Lifesciences

Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.

Founded

1982

HQ

Employees

5.5K

Website

megawecare.com

Sectors

BiopharmaceuticalsHealth & BeautyNutraceuticals & CosmeceuticalsBioTech

Financials (LTM)

Revenue: $464M

EBITDA: $107M

EV

$802M

Valuation Multiples

Multiples.vc

Start free trial

Mega Lifesciences Financials

Mega Lifesciences reported last 12-month revenue of $464M and EBITDA of $107M.

In the same LTM period, Mega Lifesciences generated $242M in gross profit, $107M in EBITDA, and $64M in net income.

Mega Lifesciences P&L

In the most recent fiscal year, Mega Lifesciences reported revenue of $456M and EBITDA of $107M.

Mega Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Mega Lifesciences Stock Performance

Mega Lifesciences has current market cap of $925M, and enterprise value of $802M.

Mega Lifesciences' stock price is $1.06.

Mega Lifesciences Valuation Multiples

Mega Lifesciences trades at 1.7x EV/Revenue multiple, and 7.5x EV/EBITDA.

Mega Lifesciences Financial Valuation Multiples

As of April 18, 2026, Mega Lifesciences has market cap of $925M and EV of $802M.

Equity research analysts estimate Mega Lifesciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Mega Lifesciences has a P/E ratio of 14.5x.

Mega Lifesciences Margins & Growth Rates

Mega Lifesciences' revenue in the last 12 month grew by 6%.

Mega Lifesciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Mega Lifesciences' rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mega Lifesciences' rule of X is 45% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Mega Lifesciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.

Mega Lifesciences M&A Activity

Mega Lifesciences acquired XXX companies to date.

Last acquisition by Mega Lifesciences was on XXXXXXXX, XXXXX. Mega Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Mega Lifesciences Investment Activity

Mega Lifesciences invested in XXX companies to date.

Mega Lifesciences made its latest investment on XXXXXXXX, XXXXX. Mega Lifesciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).